Relay Therapeutics, Inc.
NASDAQ:RLAYBiotechnology
+$0.41 today
- Market cap
- $3.65B
- Beta
- 1.75
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$1.52
Volume 2.43M
Average 3.70M
RLAY Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Relay Therapeutics, Inc.NASDAQ: RLAY
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization declines year over year
Q2 FY2026 depreciation & amortization of $360K fell 64.1% year over year, behind the -55.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 28.6% from the prior quarter. Over 3 fiscal years it compounded at -4.9% a year.
Context
- Depreciation & amortization amounted to 23.2% of revenue in FY2025, down 31.4 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -64.1% toward the trailing-twelve-month pace of -55.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 3.56M USD
- Year-over-year change
- -34.9%
- 4-year CAGR
- -2.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.56M | -34.9% |
| FY2024 | 2024-12-31 | 5.46M | +3.7% |
| FY2023 | 2023-12-31 | 5.27M | +27.6% |
| FY2022 | 2022-12-31 | 4.13M | +5.2% |
| FY2021 | 2021-12-31 | 3.93M | — |
Depreciation & Amortization vs competitors
How RLAY compares with its peers on the latest reported figures
- RLAY's LTM Jun 2026 depreciation & amortization of $2.21M is the 7th largest of the 11 companies compared; the peer median is $2.34M.
- Its year-over-year change of -55.0% is the lowest of 10, against a peer median of +1.6%.
- Depreciation & amortization amounts to 21.4% of revenue for RLAY, versus a peer median of 5.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $18.08M | +31.1% | +19.7% | — | |
| LTM Aug 2026 | $15.87M | -14.3% | +20.4% | 2.3% | |
| LTM Jun 2026 | $8.23M | +1.6% | +40.8% | 7.8% | |
| LTM Mar 2026 | $4.6M | +18.5% | +29.8% | 2.0% | |
| LTM Mar 2026 | $3.59M | — | — | — | |
| LTM Sep 2026 | $2.89M | -9.4% | +5.6% | — | |
| LTM Jun 2026 | $2.21M | -55.0% | -4.9% | 21.4% | |
| LTM Sep 2026 | $1.79M | -26.2% | +12.4% | — | |
| LTM Mar 2026 | $1.53M | +180.4% | +0.4% | 9.2% | |
| LTM Mar 2026 | $1.19M | +3.5% | +8.1% | — | |
| LTM Mar 2026 | $541K | +0.2% | +22.6% | — | |
| Peer median (excluding RLAY) | $2.34M | +1.6% | +19.7% | 5.1% | |
Competitors are the stored peer set for RLAY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (363.87M) | (290.51M) | (341.97M) | (337.71M) | (276.48M) |
| Depreciation & Amortization | 3.93M | 4.13M | 5.27M | 5.46M | 3.56M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 48.45M | 56.14M | 86.03M | 94.14M | 62.42M |
| Change in Working Capital | 97.34M | 11.25M | (32.46M) | 14.62M | (23.31M) |
| Accounts Receivables | 77.79M | 97K | 5.22M | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 930K | 1.99M | (2.39M) | 0 | (11.44M) |
| Other Working Capital | 18.62M | 9.16M | (35.28M) | 14.62M | (11.87M) |
| Other Non-Cash Items | 139.74M | (10.5M) | (17.19M) | (25.62M) | (1.65M) |
| Operating Cash Flow | (74.41M) | (229.49M) | (300.32M) | (249.11M) | (235.46M) |
| Capital Expenditures | (3.47M) | (9.06M) | (4.13M) | (2.02M) | (410K) |
| Acquisitions (Net) | (25.3M) | 179.68M | 0 | 0 | 0 |
| Purchases of Investments | (980.67M) | (535.42M) | (385.54M) | (650.63M) | (122.97M) |
| Sales of Investments | 529.92M | 355.74M | 647.3M | 611.56M | 316.18M |
| Other Investing Activities | 0 | (179.68M) | 0 | 0 | 0 |
| Investing Cash Flow | (479.51M) | (188.75M) | 257.63M | (41.08M) | 192.8M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 382.21M | 284.74M | 30.28M | 265.89M | 1.6M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.88M | 5.17M | 4.47M | 4.26M | 0 |
| Financing Cash Flow | 388.09M | 289.91M | 34.75M | 270.15M | 1.6M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (165.83M) | (128.33M) | (7.93M) | (20.04M) | (41.05M) |
| Free Cash Flow | (77.88M) | (238.55M) | (304.44M) | (251.13M) | (235.87M) |
Relay Therapeutics, Inc.
NASDAQ:RLAY
Intrinsic Alpha fair value
Locked
Current Price
$16.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.